Biocon Biologics and Mylan announce launch of Semglee in the U.S.

▴ commercialization-insulin-glargine-us-represents-another-milestone-achievement-biocon-biologics
Biocon Biologics and Mylan announce launch of Semglee (insulin glargine injection) in the U.S. to expand access for patients living with diabetes

Biocon Biologics India Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd. and Mylan  today announced the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of diabetic ketoacidosis. Semglee, which received final approval from the U.S. Food and Drug Administration (FDA), has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications.

Dr Thomas Blevins, M.D., lead investigator for the INSTRIDE clinical trials, said: “The availability of Semglee provides another quality treatment option for patients living with diabetes in the U.S. We rigorously compared Semglee (insulin glargine injection) to the reference insulin glargine in participants with Type 1 and 2 diabetes and found that Semglee yielded similar (non-inferior) glycemic results in both groups. The safety, including immunogenicity, was similar too. As a result, this insulin was approved by the FDA for the same indications as its reference product Lantus, thus expanding access for millions of people within this important patient community.”

To encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC) of $147.98 per package of five 3ml pens and $98.65 per 10ml vial, representing the lowest WAC for any long-acting insulin glargine on the market. The list price of Semglee pen is equivalent to the Lantus launch price in 2007, and the Semglee vial is listed at Lantus’s 2010 pricing. Eligible patients may also qualify for patient assistance and/or a co-pay card, similar to other medications in this class. Additionally, Mylan has submitted to FDA all necessary documentation to request approval of Semglee as a biosimilar to Lantus under the 351(k) pathway and remains confident in seeking an interchangeability designation.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon said: “The commercialization of our insulin glargine in the U.S. represents another milestone achievement for Biocon in making insulin-based therapy increasingly accessible for people with diabetes globally. We are confident that along with our long-standing partner Mylan, we will be able to address the needs of millions of patients living with diabetes in the U.S. Leveraging our science and global scale manufacturing expertise, we have been expanding affordable access to biosimilar insulins to patients in Japan, Australia, Europe, India and key emerging markets. The U.S. launch of Semglee takes us closer to realizing our aspiration of reaching ‘one in five’ insulin dependent people with diabetes worldwide.”

Dr Christiane Hamacher, CEO, Biocon Biologics said: “It is indeed a proud moment for Biocon Biologics to make Semglee (insulin glargine injection) available to patients in the U.S. Our unwavering focus on developing and manufacturing global quality insulins enables us to address the growing needs of diabetes patients and the healthcare systems. We stay committed to expand affordable access to life-saving global quality biosimilars and insulin analogs and generating savings for the U.S. healthcare system. We believe the U.S. market represents a great opportunity for us and expect Semglee to contribute significantly to our goal of impacting 5 million patients’ lives and achieving $1 billion revenue by end of FY22.”

Mylan CEO Heather Bresch said: “We are proud to be the first company, following the reference product, to receive FDA approval on and launch both the vial and pen presentations of an insulin glargine treatment with an identical amino acid sequence to Sanofi's Lantus. Even more importantly, we are proud to make Semglee available to more than 30 million Americans living with diabetes in the U.S., providing more treatment options and increasing access. While providing our product at the most competitive list price on the market is an important step towards ensuring that those who need insulin are able to access and afford it, we also know that there is still work to be done to ensure this access and affordability reaches patients at the pharmacy counter. We remain committed to work across the healthcare system to improve outcomes for all.”

Mylan President Rajiv Malik said: “Bringing to market both the vial and pen presentations of Semglee, the first for any company following the reference product, required years of investment and commitment, and represents another important example of the power of the unique platform we’ve built along with our partner Biocon Biologics in terms of our research and development, regulatory, legal and commercial expertise. Today’s launch also furthers our continued efforts to serve patients through the availability of a full portfolio of short- and long-acting insulins, which also includes our insulin aspart that we expect to launch next year. Our near-term strategy to ensure the availability of Semglee will require a strategic and targeted phased launch approach. Over the long term, we expect this addition to our portfolio to play an increasingly important role within our global biosimilars and insulin analog franchise as well as our efforts to advance access to complex medicines.”

Mylan and Biocon Biologic’s insulin glargine has received regulatory approval in more than 45 countries around the world and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.

Tags : #BioconBiologics #Mylan #USFDA #KiranMazumdarShaw #RajivMalik #HeatherBresch #USHealthcareSystem #DrChristianeHamacher #Diabetes

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-


Trending Now

Symptoms and tips for care while dealing with heart diseasesOctober 01, 2022
Natural Ways to Treat Baby Cold CoughOctober 01, 2022
Gall Bladder Stone Pain October 01, 2022
International Day For Older Persons 2022October 01, 2022
Uwal Healthcare can provide high quality generic medicines at 15 to 16% lower costOctober 01, 2022
8 Extremely deadly symptoms you Need to Know about Herpes Simplex VirusSeptember 30, 2022
8 Extremely deadly symptoms you Need to Know about Herpes Simplex VirusSeptember 30, 2022
Post-abortion diet for faster recovery – Foods to eat and to avoidSeptember 30, 2022
Post-abortion diet for faster recovery – Foods to eat and to avoidSeptember 30, 2022
Post-abortion diet for faster recovery – Foods to eat and to avoidSeptember 30, 2022
Resolute -A digital wellness platform providing Hyper-Personalised holistic solutionsSeptember 30, 2022
World Heart Day 2022 – Eat heart-healthy to keep your heart healthySeptember 29, 2022
Loneliness - A deadly cause of your depression you must knowSeptember 29, 2022
Loneliness - A deadly cause of your depression you must knowSeptember 29, 2022
Loneliness - A deadly cause of your depression you must knowSeptember 29, 2022
Know About PCOS Awareness Month-2022 September 29, 2022
What is long covid and how does it affect the body? September 29, 2022
Calcium is essential for smooth functioning of the body and good bone healthSeptember 28, 2022
World Rabies Day 2022 – Rabies symptoms and standard treatmentSeptember 28, 2022
Drinking Amla water gives health 8 tremendous benefitsSeptember 28, 2022